Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinol dehydrogenase 12 (RDH12)
- Target
- RDH12
- Molecular classification
- Enzyme, Oxidoreductase, Short-chain dehydrogenase/reductase (SDR) family
01
Overview
Retinol dehydrogenase 12 (RDH12) is a member of the short-chain dehydrogenase/reductase family primarily expressed in the inner segments of retinal photoreceptors. The enzyme catalyzes the NADPH-dependent reduction of all-trans- and 11-cis-retinal to their respective retinols, playing a key role in the visual cycle and protecting photoreceptor cells from toxic aldehydes—byproducts of light exposure and lipid peroxidation. Mutations in RDH12 are associated with severe inherited retinal dystrophies, such as Leber congenital amaurosis. In addition to the retina, RDH12 is expressed at lower levels in other tissues, including kidney, liver, pancreas, and brain, suggesting broader aldehyde detoxification functions.
- Other names
- RDH12Short chain dehydrogenase/reductase family 7C member 2 (SDR7C2)all-trans and 9-cis retinol dehydrogenase
02
Mechanism of action
Enzyme inhibition (e.g., competitive inhibition of oxidoreductase activity by retinoic acid derivatives)
03
Biological functions
Visual cycleRetinoid metabolismDetoxification of aldehydesCellular protection from oxidative and endoplasmic reticulum stress
04
Disease associations
Retinal diseases (e.g., Leber congenital amaurosis, retinitis pigmentosa)Neurodegenerative disease (retinal degeneration)Other (photoreceptor protection, cellular stress response)
05
Safety considerations
Potential risk of vision loss due to deficiency or mutationaccumulation of toxic retinal byproducts resulting in photoreceptor degeneration
06
Interacting drugs
Isotretinoin (13-cis-retinoic acid, competitive inhibitor of some retinol dehydrogenases)
1 more in the full profile.
07
Biomarkers
RDH12 mutations as biomarkers for inherited retinal dystrophies and response to emerging gene therapies
Beyond the preview
Go deeper on Retinol dehydrogenase 12 (RDH12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Retinol dehydrogenase 12 (RDH12).